Regulatory Environment In DMD Encourages BioMarin Bet On Prosensa
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite Phase III failure under a previous partnership with GSK, the orphan specialist could be the right partner at the right time as drisapersen heads for accelerated approval for Duchenne muscular dystrophy.